Skip Navigation

JNCI Journal of the National Cancer Institute 1997 89(20):1524-1529; doi:10.1093/jnci/89.20.1524
© 1997 by Oxford University Press
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Liu, B.
Right arrow Articles by Yu, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, B.
Right arrow Articles by Yu, D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal Of The National Cancer Institute, Vol 89, 1524-1529, Copyright © 1997 by Oxford University Press


ARTICLES

Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1)

B Liu, D Sun, W Xia, MC Hung and D Yu
Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

BACKGROUND: Increased expression of the multidrug resistance gene (MDR- 1)-encoded P-glycoprotein (p170[mdr-1]) is a major cause of tumor cell multidrug resistance. p170(mdr-1) functions as a drug-efflux pump to reduce the cellular accumulation of specific drugs. MDA-MB-435 human breast cancer cells that have been transfected with oncogene c-erbB2 complementary DNA (435.eb cells) express high levels of the transmembrane glycoprotein p185(c-erbB2) and exhibit increased resistance to the chemotherapeutic agent paclitaxel via p170(mdr-1)- independent mechanisms. We have recently discovered that the widely used monoclonal antibody C219, which is specific for p170(mdr-1), may cross-react with p185(c-erbB2) in 435.eb cells. In this study, we have investigated the nature of this cross-reactivity. METHODS: Immunoprecipitation experiments involving the use of breast cancer cells that express different levels of p185(c-erbB2) were performed, and C219 was used for western blot analysis of immunoprecipitated proteins. Immunohistochemical analyses were performed on acetone-fixed slides of human breast cancer cells. Peptide sequence comparisons and enzyme-linked immunosorbent assays were performed to determine the molecular basis of C219 cross-reactivity with p185(c-erbB2). RESULTS: The cross-reactivity of C219 with p185(c-erbB2) was demonstrated by both western blot and immunohistochemical analyses. Peptide sequence comparisons revealed that C219 recognizes an epitope in p170(mdr-1) (C219 epitope) that shares sequence homology with p185(c-erbB2). Enzyme- linked immunosorbent assays demonstrated that C219 recognizes synthetic peptides derived from both the C219 epitope in p170(mdr-1) and the C219 epitope-homologous region in p185(c-erbB2). CONCLUSIONS: The anti- p170(mdr-1) monoclonal antibody C219 cross-reacts with p185(c-erbB2) through a peptide sequence in p185(c-erbB2) that is homologous to the C219 epitope in p170(mdr-1).
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
L. Couture, J. A. Nash, and J. Turgeon
The ATP-Binding Cassette Transporters and Their Implication in Drug Disposition: A Special Look at the Heart.
Pharmacol. Rev., June 1, 2006; 58(2): 244 - 258.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. G. Thomas, T. J. Giordano, D. Sanders, J. S. Biermann, and L. Baker
Absence of HER2/neu Gene Expression in Osteosarcoma and Skeletal Ewing's Sarcoma
Clin. Cancer Res., March 1, 2002; 8(3): 788 - 793.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
S. M. Sisodiya, W.-R. Lin, B. N. Harding, M. V. Squier, and M. Thom
Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy
Brain, January 1, 2002; 125(1): 22 - 31.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. S. Wunder, S. B. Bull, V. Aneliunas, P. D. Lee, A. M. Davis, C. P. Beauchamp, E. U. Conrad, R. J. Grimer, J. H. Healey, M. J. Rock, et al.
MDR1 Gene Expression and Outcome in Osteosarcoma: A Prospective, Multicenter Study
J. Clin. Oncol., July 14, 2000; 18(14): 2685 - 2694.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. M. H. van den Elsen, D. A. Kuntz, F. J. Hoedemaeker, and D. R. Rose
Antibody C219 recognizes an alpha -helical epitope on P-glycoprotein
PNAS, November 23, 1999; 96(24): 13679 - 13684.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Venditti, G. Del Poeta, F. Buccisano, A. Tamburini, M. Christina Cox-Froncillo, A. Bruno, B. Del Moro, A. Maria Epiceno, M. Masi, S. Amadori, et al.
Biological Features of Acute Myeloid Leukemia in the Elderly
Blood, July 15, 1998; 92(2): 697 - 699.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.